Frederico

VAR2 Pharmaceuticals is attending the American Association Cancer Research Annual Meeting taking place in California between April 17 and 22. Our Executive Chairman of the Board and company co-founder Mads Daugaard will be on site and presenting a poster (CT112) on the clinical validation of our anti-oncofetal chondroitin sulfate Vartumabs in our ongoing Phase 0 […]

Acute Myeloid Leukemia (AML) is one of the most common acute leukemia in adults and still with a large unmet need for new therapies. The 5-year overall survival (OS) rate of AML is ~30%, and standard treatment regimens have changed remarkably little since the 1970s. In particular, antibody drug conjugates (ADCs) have fallen short of […]

Our team is attending the 16th Annual World ADC Event in London, UK happening between the 23rd and the 26th of February 2026. Our CEO Ali Salanti will deliver an invited talk on Tuesday 24th February 2026 at 2:30 PM local time. We are looking forward to meeting old and new partners to discuss synergies […]

 The development of new, clinically-effective Antibody Drug Conjugates (ADCs) has been hampered by a lack of suitable target antigens, particularly those which target both cancer and cancer-supporting stromal cells.  Oncofetal chondroitin sulfate (ofCS) is an attractive target in this regard, as it is not only broadly expressed across many solid tumors while being largely absent […]

VAR2 Pharma will join BIO-Europe in Vienna between Nov 3-5.  Our CEO Prof. Ali Salanti will present our company and program on Nov 3 at 14:15 in Theater 2. Ali will share data from our ongoing first-in-human imaging trial and how we are quickly translating the first of its kind antibody drug conjugate targeting oncofetal […]

Our CEO and founder Ali Salanti will be delivering an invited talk alongside other European and global leaders innovating in the antibody drug conjugate (ADC) space at the 15th World ADC London conference, scheduled to take place in London between March 3rd and 6th . Ali will share with the audience our recent progress in […]

GRONINGEN, NETHERLANDS (21 January 2025) – TRACER and VAR2 Pharma announce the first patient enrolled in the VARTUTRACE study, a Phase 0 first-in-human imaging trial (NCT06645808). The patient, suffering from lung carcinoma received the Investigational Medicinal Product (IMP), a zirconium-89-labeled single-chain variable fragment (scFv), Vartumab, on Dec 17, 2024. The patient successfully completed all study […]

Our team is attending the World ADC Event Series taking place in San Diego between Nov 4-7. Our CEO Ali Salanti will be accompanied by Tobias Gustavsson, Swati Choudhary, Robert Dagil and Thomas Clausen. We are looking forward to meeting old and new partners to discuss synergies around our lead ADC based on first-in-class antibodies […]

GRONINGEN, NETHERLANDS (30 September 2024) – VAR2 Pharmaceuticals ApS (‘VAR2 Pharma’) has received regulatory approval for their first-in-human Phase 0 clinical trial. In this study, the safety, tolerability, and biodistribution of two zirconium-89 labeled single-chain variable Fragments (scFvs) will be evaluated using PET/CT molecular imaging. The Danish company VAR2 Pharma is collaborating with TRACER, a […]

Our team is attending ESMO 2024 in Barcelona! VARCT Dx’s CSO, Mette Ørskov Agerbæk and VAR2 Pharma’s COO Frederico Pimenta will be there and are looking forward to catching up on the most recent developments in oncology. Come meet us at our poster #218P on Sunday to hear more about our latest work on using […]